Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$32.12 USD
+0.08 (0.25%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $32.03 -0.09 (-0.28%) 4:26 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for Tarsus Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 227 | 217 | 172 | 168 | 58 |
Receivables | 18 | 4 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 0 | 0 | 0 | 0 |
Other Current Assets | 8 | 5 | 4 | 2 | 0 |
Total Current Assets | 256 | 225 | 176 | 171 | 58 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 0 |
Investments & Advances | 1 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 4 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 1 | 1 | 0 | 0 |
Total Assets | 265 | 228 | 179 | 172 | 58 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 24 | 10 | 9 | 4 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 13 | 6 | 3 | 1 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 37 | 15 | 11 | 5 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 30 | 19 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 0 | 1 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 69 | 35 | 12 | 6 | 1 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 63 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 442 | 302 | 213 | 199 | 0 |
Retained Earnings | -245 | -109 | -47 | -33 | -6 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 197 | 193 | 167 | 166 | 57 |
Total Liabilities & Shareholder's Equity | 265 | 228 | 179 | 172 | 58 |
Total Common Equity | 197 | 193 | 167 | 166 | -6 |
Shares Outstanding | 33.10 | 26.60 | 20.60 | 20.30 | NA |
Book Value Per Share | 5.95 | 7.25 | 8.09 | 8.18 | 0.00 |
Fiscal Year End for Tarsus Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 227 | 247 | 178 | 201 |
Receivables | NA | 18 | 6 | 0 | 3 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 3 | 0 | 0 | 0 |
Other Current Assets | NA | 8 | 6 | 5 | 5 |
Total Current Assets | NA | 256 | 259 | 183 | 209 |
Net Property & Equipment | NA | 1 | 2 | 2 | 1 |
Investments & Advances | NA | 1 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 4 | 4 | 0 | 0 |
Deposits & Other Assets | NA | 2 | 1 | 1 | 1 |
Total Assets | NA | 265 | 268 | 189 | 211 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 24 | 15 | 9 | 9 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 13 | 8 | 5 | 4 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 37 | 23 | 15 | 13 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 30 | 30 | 25 | 25 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 2 | 2 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 69 | 55 | 41 | 38 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 442 | 416 | 311 | 306 |
Retained Earnings | NA | -245 | -203 | -164 | -132 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 197 | 214 | 148 | 173 |
Total Liabilities & Shareholder's Equity | NA | 265 | 268 | 189 | 211 |
Total Common Equity | 0 | 197 | 214 | 148 | 173 |
Shares Outstanding | 34.20 | 33.10 | 33.10 | 26.80 | 26.80 |
Book Value Per Share | 0.00 | 5.95 | 6.45 | 5.51 | 6.47 |